Home › Castration-Resistant Prostatic Cancer › Pennsylvania
Castration-Resistant Prostatic Cancer clinical trials in Pennsylvania
5 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Lehigh Valley Hospital, Allentown
- MidLantic Urology, Bala-Cynwyd
- Penn State Milton S. Hershey Medical Center, Hershey
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- MidLantic Urology, Bala-Cynwyd
- Keystone Urology Specialists, Lancaster
- Penn Medicine Abramson Cancer Center, Philadelphia
- and 1 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06863272A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Penn State Milton S. Hershey Medical Center, Hershey
- Thomas Jefferson University Honickman Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.